EGFR inhibitors

Afatinib - Cetuximab - Dacomitinib - Erlotinib - Gefitinib - Lapatinib - Osimertinib      

Select            
Trial Studied trt Control trt patientstagsROB Trial resultprogression or death (progression free survival PFS) death (overall survival)

lung cancer (metastatic)

afatinib
LUX-LUNG 3, 2015         afatinibcisplatin-based chemotherapy -
LUX-LUNG 6, 2015       afatinibcisplatin-based chemotherapy -
cetuximab
Lynch, 2010     cetuximabCTRisk of bias negative-10%-11%
Butts, 2007     cetuximabCT alone -
FLEX (Pirker), 2009      NCTcetuximab + CTCT alonesuggesting-13%
Rosell, 2008     cetuximab + CTCT alone -
dacomitinib
ARCHER 1050      NCTdacomitinibgefitinib -
erlotinib
OPTIMAL     erlotinibPlatinum-based CT EGFR mutations Risk of bias suggesting-84%
EUTRAC     erlotinibPlatinum-based CT 1st line EGFR mutations Risk of bias suggesting-63%
TITAN       erlotinibPlatinum-based CT 2nd line Risk of bias negative-4%
TRIBUTE (Herbst)     erlotinib + Platinum-based CTPlatinum-based CT 1st line negative
Gatzemeier     erlotinib + Platinum-based CTPlatinum-based CT 1st line negative-2%
Mok     erlotinib + Platinum-based CTPlatinum-based CT 1st line suggesting-29%9%
SATURN (Cappuzzo)     erlotinib + Platinum-based CTPlatinum-based CT maintenance therapy suggesting-19%
Boutsikou     erlotinib + Platinum-based CTPlatinum-based CT 1st line negative-19%
Lee     erlotinib + Platinum-based CTPlatinum-based CT 2nd line suggesting-42%-25%
Stinchcombe   erlotinib + Platinum-based CTPlatinum-based CTnegative-13%20%
FASTACT-2 (Wu)     erlotinib + Platinum-based CTPlatinum-based CT 1st line suggesting-43%-21%
gefitinib
West Japan   gefitinib -
Northeast Japan   gefitinib -
CTONG0806 (Yang), 2013   gefitinib - 96%
NEJ002, 2013     gefitinibcarboplatin-paclitaxel1L -
Maemondo, 2010       gefitinibcarboplatin-paclitaxel2L -
IPASS (Mok), 2009      NCTgefitinibcarboplatin-paclitaxel1L -
IPASS           gefitinibcarboplatin/paclitaxel1L -
WJTOG3405 (Mitsudomi), 2010     gefitinibcisplatin plus docetaxel -
WJTOG0203 (Takeda), 2010     gefitinibcontinued platinum-doublet chemotherapy -
ISTANA (Lee), 2010     gefitinibdocetaxel2Lsuggesting-27%-13%
V-15-32 (Maruyama), 2008         gefitinibdocetaxel2Lsuggesting-10%12%
INTEREST (Kim), 2008   gefitinibdocetaxel2Lnegative4%1%
SIGN (Cufer), 2006   gefitinibdocetaxel2Lnegative-6%-3%
IFCT-0301 study (Morère), 2010     gefitinibdocetaxel -
Kris, 2003     gefitinibgefitinib2LLow risk of bias -
First Signal       gefitinibgemcitabine and cisplatin1L -
INTACT 2, 2004     gefitinib paclitaxel and carboplatinpaclitaxel and carboplatin1LLow risk of bias -
NCIC CTG BR19 (Goss), 2013     gefitinibplaceboLow risk of bias -
INFORM; C-TONG 0804, 2012      NCTgefitinibplacebo -
EORTC 08021/ILCP 01/03, 2011      NCTgefitinibplacebo2L -
Goss, 2009     gefitinibplacebo1L -
SWOG S0023 (Kelly), 2008     gefitinibplacebo -
ISEL, 2006       gefitinibplacebo2L -
Tsuboi, 2005     gefitinibplacebo -
INTACT 1.     gefitinib + gemcitabine/cisplatinplacebo + gemcitabine / cisplatin1LLow risk of bias -
INVITE (Crinò), 2008      NCTgefitinibvinorelbine1L -
osimertinib
FLAURA, 2017      NCTosimertinibplacebo1LLow risk of bias suggesting -55%
AURA 3, 2017    NCTosimertinibplatinum-based therapy plus pemetrexed 2Lsuggesting-70%